Effect of additional intravenous immunoglobulin for infliximab-refractory Kawasaki disease: a cohort study
Main finding · Time until fever resolutionResult — go to the resultHR for fever resolution 1.00 95% CI 0.58–1.70Authors' conclusion
Additional IVIG for IFX-refractory KD may have a therapeutic effect comparable to that of the second IVIG for IVIG-resistant KD and be a hopeful therapeutic option for IFX-refractory KD.
Study context
- Population
- Patients with Kawasaki disease refractory to infliximab, single centre
- Participants
- 27 vs 38
- Exposure
- Additional intravenous immunoglobulin (IVIG) after infliximab (IFX) for IFX-refractory Kawasaki disease (KD) vs second IVIG for IVIG-resistant KD
- IVIG-after-IFXn = 27
- second-IVIGn = 38reference
- Outcome
- Time from initiation of treatment to resolution of fever
Methodological detailssingle-centre, descriptive statistics and survival analysis
- Single-centre
- Descriptive statistics and survival analysis
Main finding
Time until fever resolution
HR for fever resolution
1.00
95% CI 0.58–1.70
P = 0.783
By group
IVIG-after-IFXvs Second-IVIG
HR for fever resolution 1.00 (95% CI 0.58–1.70); P = 0.783
As reported in the abstract
Observational data: associations, not effects.
Further findings
Fever resolved within 2.0 days after therapy initiation
Coronary artery lesions (CALs) before initiating IVIG-after-IFX
- CALs identified before initiating IVIG-after-IFX
- 26% (7/27)
New CALs after IVIG after IFX
- New CALs after IVIG after IFX
- 7% (2/27)
Persistent CALs · 12 months after diagnosis
- Persistent CALs after 12 months after diagnosis
- 19% (5/27)
Original publication
Effect of additional intravenous immunoglobulin for infliximab-refractory Kawasaki disease: a cohort study. Pediatr Rheumatol Online J. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →